Marc Brazie, MD
Nephrology · Clinton, MDNPI 1770627176
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 95.9% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $6,507, more than ten times the $19 reported in 2020.
Across 18 payments — averaging $365.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$6K
- Nxstage Medical, Inc.$190
- Medtronic$34
- Akebia Therapeutics Inc$25
- Amgen$19
- Travere Therapeutics, Inc.$0
What the payments were for
- Consulting fees$2,40036%
- Travel & lodging$2,97745%
- Food & beverage$1,16018%
- Education$461%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 10 | $6,316 |
| Nxstage Medical, Inc. | 3 | $190 |
| Medtronic | 2 | $34 |
| Akebia Therapeutics Inc | 1 | $25 |
| Amgen | 1 | $19 |
| Travere Therapeutics, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,583 in reported general payments places this provider in the 85th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 152 | $147,726 |
| JardianceEmpagliflozin | 63 | $86,076 |
| EntrestoSacubitril/Valsartan | 11 | $7,345 |
| Nifedipine ErNifedipine | 29 | $1,895 |
| Torsemide | 36 | $1,740 |
| Calcium Acetate | 13 | $1,305 |
| Losartan Potassium | 100 | $1,050 |
| Calcitriol | 33 | $674 |
| Valsartan | 20 | $618 |
| Spironolactone | 45 | $603 |
| Chlorthalidone | 21 | $602 |
| Tamsulosin Hcl | 19 | $542 |
| Carvedilol | 61 | $541 |
| Hydralazine Hcl | 32 | $533 |
| Atorvastatin Calcium | 32 | $470 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Clinton
- Cindy HuangClinton$7K
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Eli RozaHagerstown$79K
- Mohamed AttaBaltimore$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.